CN112654363A - 组织特异性wnt信号增强分子和其用途 - Google Patents

组织特异性wnt信号增强分子和其用途 Download PDF

Info

Publication number
CN112654363A
CN112654363A CN201980052962.2A CN201980052962A CN112654363A CN 112654363 A CN112654363 A CN 112654363A CN 201980052962 A CN201980052962 A CN 201980052962A CN 112654363 A CN112654363 A CN 112654363A
Authority
CN
China
Prior art keywords
polypeptide
molecule
wnt signaling
wnt
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980052962.2A
Other languages
English (en)
Chinese (zh)
Inventor
张正健
李阳
叶文琛
袁之邺
海琳·巴里博
赖国宝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surrozen Inc
Original Assignee
Surrozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surrozen Inc filed Critical Surrozen Inc
Publication of CN112654363A publication Critical patent/CN112654363A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980052962.2A 2018-07-09 2019-07-09 组织特异性wnt信号增强分子和其用途 Pending CN112654363A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862695509P 2018-07-09 2018-07-09
US62/695,509 2018-07-09
US201862770026P 2018-11-20 2018-11-20
US62/770,026 2018-11-20
US201962822731P 2019-03-22 2019-03-22
US62/822,731 2019-03-22
PCT/US2019/041067 WO2020014271A1 (en) 2018-07-09 2019-07-09 Tissue-specific wnt signal enhancing molecules and uses

Publications (1)

Publication Number Publication Date
CN112654363A true CN112654363A (zh) 2021-04-13

Family

ID=69142996

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052962.2A Pending CN112654363A (zh) 2018-07-09 2019-07-09 组织特异性wnt信号增强分子和其用途

Country Status (7)

Country Link
US (1) US12466884B2 (https=)
EP (1) EP3820499A4 (https=)
JP (1) JP2021530223A (https=)
CN (1) CN112654363A (https=)
AU (1) AU2019301633A1 (https=)
CA (1) CA3104868A1 (https=)
WO (1) WO2020014271A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246570A1 (zh) * 2022-06-20 2023-12-28 广东克冠达医药科技有限公司 白介素-9的抗体及其用途
WO2023250291A3 (en) * 2022-06-21 2024-02-08 Surrozen Operating, Inc. Modulation of wnt signalling in corneal disorders
US12297278B2 (en) 2017-12-19 2025-05-13 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN111655729B (zh) 2017-12-19 2023-10-20 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11713461B2 (en) * 2019-06-21 2023-08-01 Regeneran Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4107189A4 (en) * 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
CN115427446A (zh) * 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
WO2021252804A1 (en) * 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
TW202233656A (zh) * 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
CN112426526B (zh) * 2021-01-25 2021-04-06 北京达熙生物科技有限公司 一种nk细胞的制备方法及其在治疗癌症中的应用
WO2023060277A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
EP4608445A1 (en) * 2022-10-26 2025-09-03 Research Development Foundation Cell targeting constructs and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080471A (zh) * 2011-10-14 2014-10-01 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
CN104704001A (zh) * 2012-08-09 2015-06-10 罗切格利卡特公司 Asgpr抗体及其用途
CN106714831A (zh) * 2014-04-21 2017-05-24 艾伯维施特姆森特克斯有限责任公司 新的抗‑rnf43抗体和使用方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
PL2157192T3 (pl) 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CN101573383B (zh) 2006-06-21 2015-05-13 肿瘤疗法科学股份有限公司 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
WO2008093646A1 (ja) 2007-02-01 2008-08-07 National University Corporation NARA Institute of Science and Technology Wntシグナル伝達系活性化ペプチド
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
ES2579909T3 (es) 2009-02-03 2016-08-17 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
WO2010092457A1 (en) 2009-02-10 2010-08-19 Nokia Corporation Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment
EP2305274A1 (en) 2009-09-21 2011-04-06 Centre National de la Recherche Scientifique (CNRS) Use of WNT stimulators for treating demyelinating diseases
PT2510012T (pt) 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
EP2694660B1 (en) 2011-04-03 2018-08-08 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
WO2013071047A1 (en) 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
EP2820151B1 (en) 2012-02-28 2020-03-25 Novartis AG Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US11142577B2 (en) 2014-09-12 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University WNT signaling agonist molecules
US10259874B2 (en) 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
CA2983008A1 (en) 2015-04-17 2016-10-20 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
AU2016365834B2 (en) 2015-12-08 2023-09-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US20170349659A1 (en) 2016-06-03 2017-12-07 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
EP3619238A4 (en) 2017-05-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY INDUCING THERAPEUTIC
GB201708330D0 (en) 2017-05-24 2017-07-05 Koninklijke Nederlandse Akademie Van Wetenschappen Fusion protein for enhancing intestinal regeneration
CN111655729B (zh) 2017-12-19 2023-10-20 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CA3104526A1 (en) 2018-07-05 2020-01-09 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
US20220064337A1 (en) 2018-12-19 2022-03-03 Surrozen, Inc. Antigen binding formats for receptor complexes
JP7663501B2 (ja) 2019-02-11 2025-04-16 スロゼン オペレーティング， インコーポレイテッド 眼障害におけるｗｎｔシグナル伝達の調節
US20220195053A1 (en) 2019-03-11 2022-06-23 Surrozen Operating Inc. Modulation of wnt signaling in gastrointestinal disorders
US20220175884A1 (en) 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
CN120025448A (zh) 2019-06-11 2025-05-23 安托拉诊疗公司 多价fzd和wnt结合分子及其用途
US11050604B2 (en) 2019-07-01 2021-06-29 Rampart Communications, Inc. Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
CN115427446A (zh) 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
JP2024509266A (ja) 2021-03-10 2024-02-29 スロゼン オペレーティング， インコーポレイテッド 胃腸障害におけるｗｎｔシグナル伝達のモジュレーション
WO2023044348A1 (en) 2021-09-14 2023-03-23 Surrozen Operating, Inc. Modulation of wnt signalling in pulmonary disorders
EP4448009A4 (en) 2021-12-17 2025-12-10 Surrozen Operating Inc WNT SUBSTITUTION AGENTS AND LACRYMAL GLAND REGENERATION METHODS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080471A (zh) * 2011-10-14 2014-10-01 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
CN104704001A (zh) * 2012-08-09 2015-06-10 罗切格利卡特公司 Asgpr抗体及其用途
CN106714831A (zh) * 2014-04-21 2017-05-24 艾伯维施特姆森特克斯有限责任公司 新的抗‑rnf43抗体和使用方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12297278B2 (en) 2017-12-19 2025-05-13 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
WO2023246570A1 (zh) * 2022-06-20 2023-12-28 广东克冠达医药科技有限公司 白介素-9的抗体及其用途
WO2023250291A3 (en) * 2022-06-21 2024-02-08 Surrozen Operating, Inc. Modulation of wnt signalling in corneal disorders

Also Published As

Publication number Publication date
EP3820499A1 (en) 2021-05-19
EP3820499A4 (en) 2022-07-13
US12466884B2 (en) 2025-11-11
CA3104868A1 (en) 2020-01-16
AU2019301633A1 (en) 2021-01-28
WO2020014271A1 (en) 2020-01-16
JP2021530223A (ja) 2021-11-11
US20210380678A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CN112654363A (zh) 组织特异性wnt信号增强分子和其用途
AU2020340881B2 (en) Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
AU2018211985B2 (en) Tissue-specific Wnt signal enhancing molecules and uses thereof
TWI891060B (zh) 編碼胃抑肽受體（ｇｉｐｒ）特異性抗體之核酸分子及製造該抗體之方法
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
CN107207604B (zh) 抗alk2抗体
KR102182485B1 (ko) 단백질 약물의 불활성화를 위한 항체 로커
KR102781241B1 (ko) 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
AU2015292406B2 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR20220167273A (ko) 항-코로나바이러스 항체 및 사용 방법
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR102724790B1 (ko) 항 cd147 항체
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
KR102569068B1 (ko) 항pd-l1 항체
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CN112204143B (zh) 抗人tlr7抗体
KR102880176B1 (ko) Apj 항체 및 이와 엘라벨라의 융합 단백질, 및 그의 약학 조성물 및 적용
CN114502151A (zh) 抗cd19抗体及其使用和制备方法
RU2808123C2 (ru) Антитело против человеческого tlr7
RU2785293C2 (ru) Антитело против cd147
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2
HK1247627A1 (zh) 多特异性fab融合蛋白及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Sirozen opratine

Address before: California, USA

Applicant before: SURROZEN, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210413